このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Serene Sleep Palatal Implant System Clinical Confirmatory Trial in Participants Who Snore or Are Diagnosed With Mild-to-moderate Obstructive Sleep Apnea (OSA).

2026年5月29日 更新者:Serene Sleep, Inc.

A Prospective, Non-Randomized, Multi-Center, Two-Arm Study Evaluating the Serene Sleep Palatal Implant System

This clinical investigation is a prospective, non-randomized, parallel-group clinical investigation conducted at two (2) investigative sites. Study participants will be assigned to one of two study groups, snoring and obstructive sleep apnea, in a parallel manner based on predefined eligibility criteria.

The study aims to evaluate and compare outcomes between the two groups under investigation. The primary endpoint for this study is to evaluate the adverse event profile of the Serene Sleep Palatal Implants, in comparison to those observed with the previously marketed Pillar Palatal Implants, in subjects treated for snoring and/or mild-to-moderate OSA.

The design allows for the concurrent enrollment and follow-up of participants in both arms, enabling direct observation of differences in safety across the groups over time.

調査の概要

状態

まだ募集していません

研究の種類

介入

入学 (推定)

26

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • San Francisco、California、アメリカ、94102
        • Aesthetic Surgery Center
        • コンタクト:
        • 主任研究者:
          • Michael R Macdonald, MD
    • Georgia
      • Evans、Georgia、アメリカ、30907
        • Augusta ENT
        • コンタクト:
        • 主任研究者:
          • Jonathan P Lindman, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

INCLUSION CRITERIA

A potential participant must meet ALL the following criteria to be enrolled into this study:

  1. Participant is ≥18 years of age.
  2. Participant has Body Mass Index (BMI) less than or equal to 30 kg/m²
  3. Participant has a tonsil grade less than or equal to 2
  4. Participant has a Friedman Tongue Position (FTP) I or II
  5. Participant is able to provide voluntary written informed consent.

For a snoring participant to be selected for the study:

  • Confirmed identification of palatal snoring

    • Investigators will utilize standard of care clinical assessment methods to confirm the presence of palatal snoring prior to enrollment. These methods may include patient-reported history, physical examination of the upper airway, and auscultation or audio recordings.
  • Confirmed elimination of potential sleep apnea diagnosis

    • If the evaluating doctor suspects that the participant may be experiencing OSA, investigators will utilize standard of care clinical assessment methods to confirm OSA.
    • A resulting AHI <5 would classify the participant as an eligible snoring subject

For an OSA participant to be selected for study:

Confirmed identification of apnea caused by palatal collapse

  • Investigators should be able to make this identification through intraoral evaluation in accordance with their standard of care
  • Confirmed mild-to-moderate classification of OSA

    • If the evaluating investigator knows or suspects that the participant may be experiencing OSA, standard of care diagnostic methods will be used as confirmation.
    • A resulting AHI between 5 and 30 would classify the participant as an eligible OSA subject.

EXCLUSION CRITERIA

A potential participant will be excluded from enrollment if ANY of the following conditions apply:

  1. A record of allergic reaction to polyethylene terephthalate (PET) / polyester
  2. An overly sensitive gag reflex
  3. Septal deviation or nasal obstruction
  4. Nasal polyps
  5. Severe seasonal allergies
  6. Soft palate length insufficient to accommodate implants
  7. Prior Diagnosis of Lingual tonsil hypertrophy
  8. Hypopharyngeal obstruction
  9. Previous pharyngeal surgery
  10. Previous upper respiratory tract cancer or radiation therapy
  11. Active respiratory tract infection
  12. Dysphagia or speech disorder
  13. Neurologic disorder
  14. Unstable psychiatric disorder
  15. Pregnant or breastfeeding
  16. History of falling asleep driving or Motor Vehicle Accident (MVA) due to sleepiness
  17. Clinical Presentation that suggests Severe OSAHS (ESS >20, participant report of choking or gasping during sleep, etc.)
  18. Marfan's Syndrome, Ehler-Danlos syndromes or other disorders of connective tissue and/or muscular tissue
  19. Other sleep disorders
  20. Other significant craniofacial anomaly
  21. Participant is participating in any of the following:

    • A study with the same or similar primary endpoint
    • Any study in which the investigator determines may interfere with the results of this study
  22. Participant is unwilling to complete all study related assessments and follow-up visits
  23. Participant is unwilling or unable to abstain from all alcohol consumption for 24 hours leading up to the intake sleep study
  24. Participant is unwilling or unable to abstain from all smoking, vaping, and/or oral tobacco products for 48 hours following the procedure
  25. Participant has any other medical condition which in the opinion of the Investigator will make participation medically unsafe or interfere with the study results

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Snoring Group
Implant with the Serene Sleep Palatal Implant System
Serene Sleep Palatal Implant System
実験的:Mild to Moderate OSA Group
Implant with the Serene Sleep Palatal Implant System
Serene Sleep Palatal Implant System

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of Participants with Implant Extrusion at 30 Days and Absence of Serious Adverse Device Effects (SADEs) [Hybrid Composite Safety Endpoint]
時間枠:From baseline to 30 days post-procedure
The primary endpoint for this study is to evaluate the adverse event profile of the Serene Sleep Palatal Implants, in comparison to those observed with the previously marketed Pillar Palatal Implants, in subjects treated for snoring and/or mild-to-moderate OSA.
From baseline to 30 days post-procedure

二次結果の測定

結果測定
メジャーの説明
時間枠
Change is Visual Analogue Scale (VAS) Score
時間枠:From baseline to 30 days post-procedure
The change in subjective snoring severity as measured by a 10 cm Visual Analogue Scale (VAS), scored 0-10, where 0 = no snoring and 10 = extremely annoying snoring (higher scores indicate worse outcome).
From baseline to 30 days post-procedure
Change in Snoring Outcomes Survey (SOS)
時間枠:From baseline to 30 days post-procedure
The change in subjective snoring as measured by the Snoring Outcomes Survey (SOS), an 8-item validated instrument assessing intensity, duration, frequency, and impact of snoring/sleep-disordered breathing symptoms.
From baseline to 30 days post-procedure

その他の成果指標

結果測定
メジャーの説明
時間枠
Change in daytime Epworth Sleepiness Scale (ESS)
時間枠:From baseline to 30 days post-procedure
The change in daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS), a validated 8-item questionnaire scored 0-24, where 0 = no daytime sleepiness and 24 = severe daytime sleepiness (higher scores indicate worse outcome).
From baseline to 30 days post-procedure
Change in Apnea-Hypopnea Index (bAHI3) via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
AHI Score calculated using a 3% oxygen desaturation threshold (bAHI3), collected via the Belun Sleep System HSAT device. Data will be anonymized; complete reports will be utilized as exploratory data.
From baseline to 30 days post-procedure
Change in Apnea-Hypopnea Index (bAHI4) via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
AHI Score calculated using a 4% oxygen desaturation threshold (bAHI4), collected via the Belun Sleep System HSAT device.
From baseline to 30 days post-procedure
Change in Minimum Oxygen Saturation (SpO₂) via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
Minimum SpO₂ recorded during the sleep study period, collected via the Belun Sleep System HSAT device.
From baseline to 30 days post-procedure
Change in Time with Oxygen Saturation ≤90% via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
Total cumulative duration during which SpO₂ was recorded at or below 90%, collected via the Belun Sleep System HSAT device.
From baseline to 30 days post-procedure
Change in Sleep Efficiency via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
Sleep efficiency calculated as the proportion of time in bed spent asleep, collected via the Belun Sleep System HSAT device.
From baseline to 30 days post-procedure
Change in Total Sleep Time (TST) via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
Total duration of sleep recorded during the study period, collected via the Belun Sleep System HSAT device.
From baseline to 30 days post-procedure
Change in Mean Pulse Rate via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
Mean pulse rate recorded during the sleep study period, collected via the Belun Sleep System HSAT device.
From baseline to 30 days post-procedure
Change in Arrhythmia Ratio via Home Sleep Apnea Test
時間枠:From baseline to 30 days post-procedure
Ratio of arrhythmic heartbeats to total heartbeats recorded during the sleep study period, collected via the Belun Sleep System HSAT device
From baseline to 30 days post-procedure
Change in Auditory Evaluation of Snoring
時間枠:From baseline to 30 days post-procedure

Outcome 6a: "Change in Objective Snoring Volume (decibels) via Audio Recording" - the change in mean snoring volume (dB) captured by at-home overnight audio recording.

Outcome 6b: "Change in Objective Snoring Frequency (Hz) via Audio Recording" - the change in dominant snoring frequency captured by at-home overnight audio recording.

From baseline to 30 days post-procedure
Proportion of Participants with Implant Migration or Trend Toward Extrusion as Assessed by Oropharyngeal Examination at 30 Days
時間枠:Date of procedure to 30 days post-implant
At each post-procedure visit (Day 7 and Day 30), the physician will conduct a standardized oropharyngeal examination to evaluate and document whether implant location has changed from the original placement position or is trending toward extrusion. Findings will be recorded as a binary outcome (yes/no change in location) and summarized descriptively.
Date of procedure to 30 days post-implant

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年6月1日

一次修了 (推定)

2026年9月1日

研究の完了 (推定)

2026年10月1日

試験登録日

最初に提出

2025年11月3日

QC基準を満たした最初の提出物

2026年5月26日

最初の投稿 (実際)

2026年5月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月1日

QC基準を満たした最後の更新が送信されました

2026年5月29日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

Palatal Implant Systemの臨床試験

購読する